2025-10-09 - Analysis Report
Okay, here's an analysis of Intuitive Surgical (ISRG) based on the provided data.

## ISRG Stock Analysis

**Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical systems and related instruments and accessories.

### 1. Performance vs. S&P 500 (VOO)

*   **ISRG Cumulative Return:** 66.91%
*   **VOO Cumulative Return:** 99.62%
*   **Absolute Deviation (ISRG - VOO):** -32.71%
*   **Deviation Range (Max: 98.9, Min: -35.1, Current: -30.0)**
*   **Relative Deviation:** 3.8

**Analysis:** ISRG has underperformed the S&P 500 over the analyzed period. The relative deviation of 3.8 suggests that ISRG's underperformance is near the lower end of its historical deviation range compared to S\&P500 (VOO).

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
| ---------- | ------ | ------ | ------ | ----- | ------ |
| 2015-2017  | 68.0%  | 77.6%  | 40.0%  | -0.1  | 43.6   |
| 2016-2018  | 64.0%  | 72.2%  | 49.0%  | -0.0  | 57.2   |
| 2017-2019  | 54.0%  | 72.2%  | 31.0%  | 0.2   | 70.6   |
| 2018-2020  | -6.0%  | 80.4%  | -29.0% | 0.3   | 97.8   |
| 2019-2021  | 29.0%  | 80.4%  | -18.0% | 0.6   | 128.8  |
| 2020-2022  | -23.0% | 80.4%  | -22.0% | 1.2   | 95.1   |
| 2021-2023  | -17.0% | 77.5%  | -18.0% | 1.7   | 120.9  |
| 2022-2024  | 36.0%  | 77.5%  | 15.0%  | 1.7   | 187.1  |
| 2023-2025  | 29.0%  | 72.7%  | -35.0% | 0.8   | 160.6  |

*   **CAGR:** Fluctuating, indicating varied growth rates across different periods.
*   **MDD:** Consistently high, suggesting significant potential drawdowns.
*   **Alpha:** Generally positive in earlier periods, but negative more recently, indicating underperformance relative to its risk.
*   **Beta:** Generally low, suggesting that the stock is not very sensitive to market movements.

### 2. Recent Price Movement

*   **Current Price:** 448.09
*   **Previous Close:** 440.94
*   **Change:** 1.62% (Significant positive change)
*   **5-Day Moving Average:** 446.82
*   **20-Day Moving Average:** 443.21
*   **60-Day Moving Average:** 468.20

**Analysis:** The stock shows a positive momentum as the price is above the 5-day and 20-day moving averages, but below the 60-day moving average. The recent 1.62% increase is a notable positive sign and might be a good indicator of short-term upward trend.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 57.87 (Neutral)
*   **PPO:** 0.44 (Neutral)
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash (2 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)"
*   **Recent (20-Day) Relative Deviation Change:** 2.4 (+) (Short-term increase)
*   **Expected Return:** 318.4% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests a favorable investment environment. The RSI and PPO are neutral, indicating neither overbought nor oversold conditions. The Hybrid Signal suggests a strong buy recommendation. The increase in relative deviation indicates a short-term positive trend and the expected return is very high.

### 4. Recent News & Significant Events

*   **FDA Approves Software Update:** Positive news, indicating innovation and regulatory compliance.
*   **AI & Imaging Integration:** Further strengthens ISRG's technology leadership.
*   **SP Platform for ASC Volume:** Signals strategic focus on growth markets.
*   **Analyst Uncertainty & Insider Buying:** Mixed signals, uncertainty could be a buying opportunity if insiders are confident.
*   **Health Care Sector Advance:** General tailwind for the sector.

**Analysis:** The news is mostly positive, highlighting technological advancements, strategic initiatives, and regulatory approvals.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~1.94)
*   **Target Price:** 576.95 (Avg)
*   **Target Price Range:** 350.00 - 685.00

**Analysis:** Analysts are generally positive on the stock with a 'Buy' rating and a target price significantly above the current price. The wide target price range suggests some uncertainty among analysts.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
| ---------- | ---- | --------- |
| 2025-07-23 | 1.84 | 2.44 B$   |
| 2025-04-23 | 1.95 | 2.25 B$   |
| 2024-10-18 | 1.59 | 2.04 B$   |
| 2024-07-19 | 1.48 | 2.01 B$   |
| 2025-07-23 | 1.48 | 2.01 B$   |

**Analysis:**

The table shows a general upward trend in both EPS and Revenue. The most recent data point (2025-07-23) shows strong revenue, but slightly lower EPS compared to the previous quarter.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | \$2.44B  | 66.31%        |
| 2025-03-31 | \$2.25B  | 64.69%        |
| 2024-12-31 | \$2.41B  | 68.04%        |
| 2024-09-30 | \$2.04B  | 67.41%        |
| 2024-06-30 | \$2.01B  | 68.30%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE     |
| ---------- | ----------- | ------- |
| 2025-06-30 | \$17.85B   | 3.69%   |
| 2025-03-31 | \$17.11B   | 4.08%   |
| 2024-12-31 | \$16.43B   | 4.17%   |
| 2024-09-30 | \$15.58B   | 3.63%   |
| 2024-06-30 | \$14.71B   | 3.58%   |

**Analysis:**

*   **Revenue:** Shows growth over the past few quarters.
*   **Profit Margin:** Remains consistently high, indicating strong profitability.
*   **Equity:** Increasing, suggesting strong capital accumulation.
*   **ROE:** Relatively stable.

### 7. 종합적 분석 (Overall Analysis)

**Summary:**

Intuitive Surgical (ISRG) is a leading medical technology company with strong financials, a "Buy" analyst consensus, and positive recent news. The stock has underperformed the S&P 500 in the recent periods, but there are strong indicators for potential future growth:

*   **Strong Fundamentals:** High profit margins, increasing revenue, and solid equity.
*   **Positive Catalysts:** FDA approvals, AI integration, and strategic market expansion.
*   **Analyst Optimism:** High target prices and buy recommendations.
*   **Technical Indicators:** Showing signs of short-term upward trend.
*   **High Expected Return:** Very high expected excess return(318.4%) from the current point.

**Considerations:**

*   **S&P 500 Undeperformance** Although recently there have been strong indicators, you should be cautious about relative weakeness to S&P 500 index.
*   **Analyst Uncertainty:** The target price range shows significant uncertainty among analysts.
*   **MRI:** Although MRI is high, you should consider the historical MDD, which is very high (70%~80%).

**Conclusion:**

Based on the analysis, ISRG appears to be a potentially attractive investment. The recent price momentum and positive news indicate a possible turnaround. However, investors should be aware of the MDD and the underperformance relative to the S&P 500 before making any investment decisions.
